339 related articles for article (PubMed ID: 20047618)
21. Bioequivalence of enteric-coated mycophenolate sodium and mycophenolate mofetil: a meta-analysis of three studies in stable renal transplant recipients.
Johnston A; He X; Holt DW
Transplantation; 2006 Dec; 82(11):1413-8. PubMed ID: 17164710
[TBL] [Abstract][Full Text] [Related]
22. Mycophenolate, clinical pharmacokinetics, formulations, and methods for assessing drug exposure.
Tett SE; Saint-Marcoux F; Staatz CE; Brunet M; Vinks AA; Miura M; Marquet P; Kuypers DR; van Gelder T; Cattaneo D
Transplant Rev (Orlando); 2011 Apr; 25(2):47-57. PubMed ID: 21190834
[TBL] [Abstract][Full Text] [Related]
23. Long-term safety and efficacy after conversion of maintenance renal transplant recipients from mycophenolate mofetil (MMF) to enteric-coated mycophenolate sodium (EC-MPA, myfortic).
Budde K; Knoll G; Curtis J; Chan L; Pohanka E; Gentil M; Seifu Y; Marrast AC; Neumayer HH;
Clin Nephrol; 2006 Aug; 66(2):103-11. PubMed ID: 16939066
[TBL] [Abstract][Full Text] [Related]
24. Similar efficacy and safety of enteric-coated mycophenolate sodium (EC-MPS, myfortic) compared with mycophenolate mofetil (MMF) in de novo heart transplant recipients: results of a 12-month, single-blind, randomized, parallel-group, multicenter study.
Kobashigawa JA; Renlund DG; Gerosa G; Almenar L; Eisen HJ; Keogh AM; Lehmkuhl HB; Livi U; Ross H; Segovia J; Yonan N;
J Heart Lung Transplant; 2006 Aug; 25(8):935-41. PubMed ID: 16890114
[TBL] [Abstract][Full Text] [Related]
25. Enteric-coated mycophenolate sodium given in combination with tacrolimus has a lower incidence of serious infections in Asian renal-transplant recipients compared with mycophenolate mofetil.
Feng JJ; Zhang LW; Zhao P; Bow LM; Tian J
Int J Clin Pract Suppl; 2015 May; (183):1-7. PubMed ID: 26176848
[TBL] [Abstract][Full Text] [Related]
26. Safety assessment of the conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in stable renal transplant recipients.
Massari P; Duro-Garcia V; Girón F; Hernández E; Juárez F; Castro C; Toledo M;
Transplant Proc; 2005 Mar; 37(2):916-9. PubMed ID: 15848574
[TBL] [Abstract][Full Text] [Related]
27. Superior efficacy of enteric-coated mycophenolate vs mycophenolate mofetil in de novo transplant recipients: pooled analysis.
Salvadori M; Bertoni E; Budde K; Holzer H; Civati G; Lien B; Arns W
Transplant Proc; 2010 May; 42(4):1325-8. PubMed ID: 20534293
[TBL] [Abstract][Full Text] [Related]
28. Enteric-coated mycophenolate sodium: therapeutic equivalence to mycophenolate mofetil in de novo renal transplant patients.
Sollinger H
Transplant Proc; 2004 Mar; 36(2 Suppl):517S-520S. PubMed ID: 15041399
[TBL] [Abstract][Full Text] [Related]
29. Cyclosporine A and tacrolimus combined with enteric-coated mycophenolate sodium influence the plasma mycophenolic acid concentration - a randomised controlled trial in Chinese live related donor kidney transplant recipients.
Huang HF; Yao X; Chen Y; Xie WQ; Shen-Tu JZ; Chen JH
Int J Clin Pract Suppl; 2014 Apr; (181):4-9. PubMed ID: 24673713
[TBL] [Abstract][Full Text] [Related]
30. Gastrointestinal quality of life improvement of renal transplant recipients converted from mycophenolate mofetil to enteric-coated mycophenolate sodium drugs or agents: mycophenolate mofetil and enteric-coated mycophenolate sodium.
Ortega F; Sánchez-Fructuoso A; Cruzado JM; Gómez-Alamillo JC; Alarcón A; Pallardó L; Morales JM; Oliver J; Guinea G;
Transplantation; 2011 Aug; 92(4):426-32. PubMed ID: 21760569
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetic and pharmacodynamic comparison of enteric-coated mycophenolate sodium and mycophenolate mofetil in maintenance renal transplant patients.
Budde K; Bauer S; Hambach P; Hahn U; Röblitz H; Mai I; Diekmann F; Neumayer HH; Glander P
Am J Transplant; 2007 Apr; 7(4):888-98. PubMed ID: 17391132
[TBL] [Abstract][Full Text] [Related]
32. Enteric-coated mycophenolate-sodium in heart transplantation: efficacy, safety, and pharmacokinetic compared with mycophenolate mofetil.
Lehmkuhl H; Hummel M; Kobashigawa J; Ladenburger S; Rothenburger M; Sack F; Dengler T; Hetzer R
Transplant Proc; 2008 May; 40(4):953-5. PubMed ID: 18555088
[TBL] [Abstract][Full Text] [Related]
33. Long-term follow-up of pediatric transplant recipients: mycophenolic acid trough levels are not a good indicator for long-term graft function.
Pape L; Ehrich JH; Offner G
Clin Transplant; 2004 Oct; 18(5):576-9. PubMed ID: 15344963
[TBL] [Abstract][Full Text] [Related]
34. Comparison of mycophenolic acid pharmacokinetic parameters in kidney transplant patients within the first 3 months post-transplant.
Pawinski T; Durlik M; Szlaska I; Urbanowicz A; Majchrnak J; Gralak B
J Clin Pharm Ther; 2006 Feb; 31(1):27-34. PubMed ID: 16476117
[TBL] [Abstract][Full Text] [Related]
35. Absorption characteristics of EC-MPS--an enteric-coated formulation of mycophenolic sodium.
Arns W; Gies M; Choi L; Zhu W; Cooper P; Yeh CM; Prasad P; Graf P; Schmouder R
Int J Clin Pharmacol Ther; 2006 Aug; 44(8):375-85. PubMed ID: 16961168
[TBL] [Abstract][Full Text] [Related]
36. Effect of conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium on maximum tolerated dose and gastrointestinal symptoms following kidney transplantation.
Shehata M; Bhandari S; Venkat-Raman G; Moore R; D'Souza R; Riad H; Bakran A; Baker R; Needham C; Andrews C
Transpl Int; 2009 Aug; 22(8):821-30. PubMed ID: 19386081
[TBL] [Abstract][Full Text] [Related]
37. The proton pump inhibitor pantoprazole and its interaction with enteric-coated mycophenolate sodium in transplant recipients.
Kofler S; Wolf C; Shvets N; Sisic Z; Müller T; Behr J; Sohn HY; Vogeser M; Shipkova M; Meiser B; Steinbeck G; Reichart B; Kaczmarek I
J Heart Lung Transplant; 2011 May; 30(5):565-71. PubMed ID: 21256049
[TBL] [Abstract][Full Text] [Related]
38. Estimation of Mycophenolic Acid Area Under the Curve With Limited-Sampling Strategy in Chinese Renal Transplant Recipients Receiving Enteric-Coated Mycophenolate Sodium.
Jia Y; Peng B; Li L; Wang J; Wang X; Qi G; Rong R; Wang L; Qiu J; Xu M; Zhu T
Ther Drug Monit; 2017 Feb; 39(1):29-36. PubMed ID: 27941535
[TBL] [Abstract][Full Text] [Related]
39. Omeprazole impairs the absorption of mycophenolate mofetil but not of enteric-coated mycophenolate sodium in healthy volunteers.
Kees MG; Steinke T; Moritz S; Rupprecht K; Paulus EM; Kees F; Bucher M; Faerber L
J Clin Pharmacol; 2012 Aug; 52(8):1265-72. PubMed ID: 21903891
[TBL] [Abstract][Full Text] [Related]
40. Limited sampling strategies drawn within 3 hours postdose poorly predict mycophenolic acid area-under-the-curve after enteric-coated mycophenolate sodium.
de Winter BC; van Gelder T; Mathot RA; Glander P; Tedesco-Silva H; Hilbrands L; Budde K; van Hest RM
Ther Drug Monit; 2009 Oct; 31(5):585-91. PubMed ID: 19704401
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]